

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter

Application No./Patent No.: 10/564,647 Filed/Issue Date: July 15, 2004Entitled: Human Antibody Molecules for IL-13Cambridge Antibody Technology Limited, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or2. an assignee of less than the entire right, title and interest.The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. [v] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.

[] Additional documents in the chain of title are listed on a supplemental sheet.

[v] Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

2 FEB 2007

Date

A-44(0)1223 471471

Telephone number

ADRIAN KEMP

Typed or printed name

AKG

Signature

COMPANY SECRETARY

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Assignors'

Phillip David Monk

of Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge,
CB1 6GH, United Kingdom

Lutz Ulrich Jochen Wilhelm Jermutus

of Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge,
CB1 6GH, United Kingdom

Ralph Raymond Minter

of Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge,
CB1 6GH, United Kingdom

Celia Patricia Shorrock

of Cambridge Antibody Technology Limited, Milstein Building, Granta Park, Cambridge,
CB1 6GH, United Kingdom

2 'The Assignee' Cambridge Antibody Technology Limited

(a company incorporated in England and Wales)

of Milstein Building, Granta Park, Cambridge, CB1 6GH, United Kingdom

Recitals:

(A) The Assignors are the joint inventors of the invention or inventions entitled HUMAN ANTIBODY MOLECULES FOR IL-13 ("the Invention") for which United Kingdom Patent Application No. GB 0407315.1 and United States Patent Application Nos. US 60/487,512, 60/558,216 and 60/573,791 ("The Priority Applications") and the International PCT Application ("the PCT Application") and the United States Patent Application ("the US Application") set forth in the schedule hereto claiming priority from the Priority Applications have been filed

(B) The Assignors are (or were at the time of the Invention) employees of the Assignee and by the terms of their employment and the operation of the United Kingdom Patents Act 1977 any rights which they would otherwise own in the Invention belong to the Assignee

(C) To facilitate the prosecution of the PCT Application and the US Application the Assignors have agreed to assign to the Assignee any and all rights title and interest they may have in to and under the Invention, the Priority Applications and the PCT Application for all countries designated therein

Operative provisions:

In consideration for the payment of £1.00 and other valuable consideration by the Assignee to the Assignors the receipt and sufficiency of which is hereby acknowledged by the Assignors:

1 The Assignors and each of them hereby sell and assign to the Assignee absolutely and free from incumbrances:

1.1 any and all of their respective rights title and interest in all countries of the world in to and under the Invention, the Priority Applications and the PCT Application and the US Application and all national and regional phases thereof and any and all divisionals, continuations and continuations-in-part thereof and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as they may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or its successors or assigns;

1.3 all such rights as they may have to claim priority from the Priority Applications in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the Priority Applications;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignors had this assignment not been made.

2 The Assignors hereby GRANT the firm of Mewburn Ellis LLP the power to insert in the Schedule to this Assignment any further identification of any patent applications in any countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of any Patent Office for recordation of this document. It is understood and agreed that the Assignee's attorneys Mewburn Ellis LLP have represented only the Assignee and will continue to represent only the Assignee with respect to the Invention.

3 The Assignors hereby UNDERTAKE that at the request and cost of the Assignee or its successors or assigns they will at all times hereafter promptly do all such acts and execute all such

documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any application for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignors hereby request the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.

5 This assignment and undertaking shall be binding upon the Assignors' heirs, executors, administrators, successors and/or assigns and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

IN WITNESS WHEREOF the parties hereto have executed this assignment and undertaking


SCHEDULE

HUMAN ANTIBODY MOLECULES FOR IL-13

International Application No.	Date
PCT/GB2004/003059	15 July 2004

US Application No.	Date
10/891,972	15 July 2004

SIGNED by)
Phillip David Monk)
on: 9 December 2005) Signature: 
in the presence of: (Witness))
Signature: K. Clarke
Name: KAREN CLARKE
Address: Mulstein Building
Cranta Park
Cambridge CB1 6GH.

SIGNED by)
Lutz Ulrich Jochen Wilhelm)
Jermutus)
on: 13 December 2005) Signature: 
in the presence of: (Witness))
Signature: K. Clarke
Name: KAREN CLARKE
Address: Mulstein Building
Cranta Park
Cambridge CB1 6GH


SIGNED by)
Ralph Raymond Minter)
on: 13 December 2005) Signature: 
in the presence of: (Witness))
Signature: K. Clarke
Name: KAREN CLARKE
Address: Mulstein Building
Cranta Park
Cambridge CB1 6GH

SIGNED by)

Celia Patricia Shorrock)

on: 25/11/05)

in the presence of: (Witness))

Signature: 

Name: Sarine Duncan

Address: 22 rue Humbert II, 38000 GRENOBLE, FRANCE

Signature: 


SIGNED for and on behalf of)

Cambridge Antibody Technology)

Limited)

on: 13 December 2005)

in the presence of: (Witness))

Signature: 

Name: KAREN CLARKE

Position: COMPANY SECRETARY

Signature: 

Name: KAREN CLARKE

Address: Muswell Building

Cambridge
CB1 3RH